Clinical trial Recruiting at 1 site Observational Ages 18 and up Women only

How a mother's immune system accepts pregnancy in the first trimester

Official title: Mechanisms of Maternal Immune Tolerance in Early Pregnancy

Run by University Hospital, Basel, Switzerland · NCT07297394 · Data updated 2026-11-12

We will test how the immune system changes in the first trimester in people undergoing IVF to see which immune patterns support implantation and help prevent early miscarriage.

Quick facts

Study typeObservational
Ages18 Years and up
SexWomen only
Enrollment100 (estimated)
SponsorUniversity Hospital, Basel, Switzerland
Academic / other
Locations1 site (Basel)
StatusRecruiting
StartedMarch 2, 2026
Main results expectedDecember 2030
Study endsDecember 2030
Registry record updatedMarch 4, 2026
Trial IDNCT07297394 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

People aged 18 or older undergoing IVF/ICSI (including those who become pregnant or experience failed implantation/miscarriage) who can provide written informed consent and attend blood draws at the study site are ideal candidates.

Probably not a fit

Individuals with HIV, hepatitis B or C, syphilis, or those taking immunosuppressive medications are excluded and thus will not be eligible, and participants should not expect direct therapeutic benefit from this observational study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, longitudinal study of people undergoing IVF/ICSI that collects blood before embryo transfer, during the first trimester, and after any miscarriage. Samples will be analyzed for immune cell composition, activation states, and cytokine profiles using advanced immunological assays. The design tracks immune changes from pre-implantation through early gestation to identify cellular and molecular signatures linked to successful implantation and tolerance. Results aim to generate markers that could inform future predictive tests or targeted interventions.

Why it matters

Potential benefit: If successful, the study could identify blood-based immune markers that help predict or prevent early pregnancy loss and guide personalized approaches to support implantation.

How similar studies have gone: Previous observational work has linked T cell subsets and cytokine patterns to pregnancy outcomes, but causal mechanisms remain unproven, so this study builds on associative findings rather than testing an established therapy.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Blood from patients will be included before and during pregnancies (or failed implantation) conceived through IVF/ICSI (Intracytoplasmic Sperm Injection) treatment and in case of miscarriage.

1. where the patient (pregnant person) was ≥ 18 years of age.
2. where the patient (pregnant person) signed a written informed consent.

Exclusion Criteria:

1. Certain maternal infections (HIV, Hepatitis B, Hepatitis C, Syphilis)
2. Patients under immunosuppressive medications (at time of blood sample collection)

Where it's running

  • University Hospital Basel
    Basel, Switzerland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.